SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia, Europe, and North America. Founded in 2011, the company has rapidly established itself as a pioneer in developing innovative therapies for neurological disorders, particularly epilepsy.
With a strong focus on research and development, SK Biopharmaceuticals has achieved significant milestones, including the successful launch of its flagship product, cenobamate, which offers unique mechanisms of action for seizure control. The company is recognised for its commitment to advancing healthcare solutions, positioning itself as a key contributor to the global biopharmaceutical landscape. Through its dedication to innovation and patient-centric approaches, SK Biopharmaceuticals continues to enhance its market presence and reputation.
0 vs industry average
SK Biopharmaceuticals’s score of 38 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at SK Biopharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
SK Biopharmaceuticals's reported carbon emissions
In 2023, SK Biopharmaceuticals reported total carbon emissions of approximately 13,000,000 kg CO2e. This figure includes 433,000 kg CO2e from Scope 1 emissions, 1,046,000 kg CO2e from Scope 2 emissions, and 11,882,000 kg CO2e from Scope 3 emissions. The company has shown a commitment to transparency in its emissions reporting, disclosing data across all three scopes. Over the past few years, SK Biopharmaceuticals has made strides in managing its carbon footprint. For instance, in 2022, the total emissions were approximately 6,547,000 kg CO2e, indicating a significant increase in emissions in 2023. The company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or SBTi commitments. As a current subsidiary of SK Inc., SK Biopharmaceuticals' emissions data is cascaded from its parent company, which may influence its overall climate strategy. However, no specific climate pledges or initiatives have been reported at this time. The company continues to focus on improving its sustainability practices while navigating the challenges of increasing emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
SK Biopharmaceuticals’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for SK Biopharmaceuticals yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from SK Inc.
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
SK Biopharmaceuticals
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project